Rejuvenate Bio’s Post

Excited to announce we received $4M in funding today from California Institute for Regenerative Medicine (CIRM) to advance IND-enabling activities for RJB-0402 for the treatment of desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM). “DSP ACM is a rare, severe, life-threatening, and debilitating disease that typically manifests in young adults as a high risk of life-threatening ventricular arrhythmias, sudden cardiac death, and progression to heart failure,” said Daniel Oliver, CEO & Co-Founder, Rejuvenate Bio. “There is currently no disease modifying therapy for patients with this disease, and our gene therapy RJB-0402 addresses a significant unmet medical need.” Read the press release: https://lnkd.in/eigtVhtm

Sharing some photos from our panel at #BIO2024 on #Increasing #Healthspan, featuring our CEO & Co-Founder Daniel Oliver. 🧬🧬🧬 Great meeting everyone last week and looking forward to the next event!

We’re excited to see everyone next month at #BIO2024! Our CEO Daniel Oliver will be speaking on a panel on Monday, June 3. Join us for an this panel discussion as we delve into the fascinating realm of longevity and explore strategies for extending our healthspan. In this engaging session, our panel of experts will unravel the science and novel therapies in development that could contribute to a longer, healthier life. More info: https://lnkd.in/eiUbyfym

Our chief scientific officer and co-founder Noah Davidsohn will be presenting at the American Society of Gene & Cell Therapy 2024 meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. 🧬🧬 “We’re excited to share data at ASGCT 2024 on our RJB-0402 gene therapy which targets key disease-mediating pathways in arrhythmogenic cardiomyopathy (ACM),” said Noah Davidsohn, PhD., Chief Scientific Officer at Rejuvenate Bio. “ACM is an inherited disease caused by mutations in one of several genes encoding desmosomal proteins, and there is an urgent need for better treatment options. If our approach proves effective to treat ACM, it would have a dramatic impact on the profound burden this disease has on patients and their families.” Title: AAV FGF21 Gene Therapy as a Variant Agnostic Treatment for Arrhythmogenic Cardiomyopathy Session Type: In-Person Oral Presentation Session Title: Next Generation Gene & Cell Therapies for Heart, Lung, and Kidney Diseases Abstract Number: 79 Location: Room 314-317 Session Date/Time: Wednesday May 8, 2024 1:30 PM - 3:15 PM Read the full release: 👇👇 https://lnkd.in/e9Qhtvws